| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2133.2007.07986.X |
| P698 | PubMed publication ID | 17553036 |
| P50 | author | Paolo Gisondi | Q56850105 |
| Andrea Conti | Q56996042 | ||
| P2093 | author name string | Giannetti A | |
| Girolomoni G | |||
| Peserico A | |||
| Piaserico S | |||
| Tessari G | |||
| Schianchi S | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metabolic syndrome | Q657193 |
| P304 | page(s) | 68-73 | |
| P577 | publication date | 2007-06-06 | |
| P1433 | published in | British Journal of Dermatology | Q4970191 |
| P1476 | title | Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study | |
| P478 | volume | 157 |
| Q39377564 | "Inflammatory skin march" in atopic dermatitis and psoriasis |
| Q42703641 | 'New to me': changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study. |
| Q37573136 | A clinical and epidemiological study of psoriasis and its association with various biochemical parameters in newly diagnosed cases |
| Q37170305 | A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. |
| Q82100704 | A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis |
| Q35564628 | A study of the prevalence of diabetes, insulin resistance, lipid abnormalities, and cardiovascular risk factors in patients with chronic plaque psoriasis |
| Q60683249 | Abordaje integral de la comorbilidad del paciente con psoriasis |
| Q37408380 | An observational study on the obesity and metabolic status of psoriasis patients |
| Q38673766 | An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies |
| Q35770123 | Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis |
| Q37998917 | Application of the dermatology life quality index in clinical trials of biologics for psoriasis |
| Q26745789 | Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis |
| Q36885064 | Assessment of adiposity in psoriatic patients by dual energy X-ray absorptiometry compared to conventional methods |
| Q87450548 | Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions |
| Q92109846 | Assessment of the Possible Role of FOXP3 Gene (rs3761548) Polymorphism in Psoriasis Vulgaris Susceptibility and Pathogenesis: Egyptian Study |
| Q34050825 | Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients |
| Q33645857 | Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis |
| Q42367098 | Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra |
| Q64386344 | Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab |
| Q26781378 | Biomarkers of An Autoimmune Skin Disease--Psoriasis |
| Q82622816 | Cardiometabolic comorbidities and the approach to patients with psoriasis |
| Q37145684 | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| Q39412708 | Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin |
| Q34638027 | Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives |
| Q90564046 | Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report |
| Q38668430 | Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. |
| Q35028089 | Clinico-biochemical correlation between psoriasis and insulin resistance |
| Q35212941 | Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study |
| Q47224549 | Double trouble: psoriasis and cardiometabolic disorders. |
| Q26771723 | Dyslipidemia in Dermatological Disorders |
| Q42119545 | Dyslipidemia in Psoriasis: A Case Controlled Study |
| Q35620533 | Effect of psoriasis activity on serum adiponectin and leptin levels. |
| Q33785074 | Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy |
| Q90207191 | Epitope Spreading Phenomenon: A Case Report |
| Q38909724 | Erectile dysfunction in patients with plaque psoriasis: the relation of depression and cardiovascular factors |
| Q41789060 | Glomerular filtration rate in patients with psoriasis treated with etanercept |
| Q35285238 | Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. |
| Q89579551 | Higher bodily adiposity, fat intake, and cholesterol serum levels are associated with higher disease activity in psoriatic arthritis patients: is there a link among fat and skin and joint involvement? |
| Q89955134 | Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study |
| Q37672346 | Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis |
| Q85932933 | Hyperuricemia in patients with chronic plaque psoriasis |
| Q89495120 | IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications |
| Q27007133 | Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis |
| Q37642111 | Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients |
| Q36906795 | Increased P-wave dispersion in patients with newly diagnosed lichen planus |
| Q34168423 | Increased prevalence of metabolic syndrome in patients with acne inversa |
| Q35086458 | Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis |
| Q46602150 | Insights into gene expression profiles induced by Socs3 depletion in keratinocytes |
| Q41880845 | Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients |
| Q37779736 | Lipid disturbances in psoriasis: an update. |
| Q34910792 | Lipid profile and metabolic syndrome status in patients with oral lichen planus, oral lichenoid reaction and healthy individuals attending a dental college in northern India - a descriptive study |
| Q40837256 | Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role? |
| Q28087039 | Management of moderate to severe psoriasis in patients with metabolic comorbidities |
| Q40114903 | Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. |
| Q37734265 | Metabolic Syndrome in Psoriasis among Urban South Indians: A Case Control Study Using SAM-NCEP Criteria |
| Q34798951 | Metabolic changes and serum ghrelin level in patients with psoriasis. |
| Q34409690 | Metabolic syndrome and its components in patients with psoriasis |
| Q93362774 | Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence |
| Q37054329 | Metabolic syndrome and skin: psoriasis and beyond |
| Q50350856 | Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients |
| Q33647531 | Metabolic syndrome in patients with psoriasis: A comparative study |
| Q36897095 | Metabolic syndrome in patients with psoriatic disease. |
| Q50127587 | Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. |
| Q36823606 | Moderate and severe plaque psoriasis: cost-of-illness study in Italy |
| Q90193044 | NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome |
| Q37027264 | National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. |
| Q37153882 | Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes |
| Q35237307 | Non-alcoholic fatty liver disease and psoriasis: So far, so near |
| Q37505690 | Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. |
| Q37778608 | Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation |
| Q35370653 | Personal history of gallstones and risk of incident psoriasis and psoriatic arthritis in U.S. women |
| Q82654527 | Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population |
| Q82610565 | Pregnancy outcomes in women with moderate‐to‐severe psoriasis |
| Q41515491 | Prevalence of Metabolic Syndrome in Psoriasis and Levels of Interleukin-6 and Tumor Necrosis Factor-α in Psoriasis Patients with Metabolic Syndrome: Indian Tertiary Care Hospital Study |
| Q51389843 | Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis |
| Q36048427 | Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years |
| Q47401344 | Prevalence of metabolic syndrome in Chinese psoriasis patients: A hospital-based cross-sectional study |
| Q36352320 | Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study |
| Q51356145 | Prevalence of metabolic syndrome in patients with psoriasis. |
| Q37644609 | Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study |
| Q55067182 | Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. |
| Q34785993 | Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. |
| Q26765028 | Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis |
| Q56115291 | Psoriasis |
| Q52319510 | Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship. |
| Q42057372 | Psoriasis and cardiomyopathy: an intriguing association. |
| Q34418506 | Psoriasis and comorbidities: links and risks |
| Q33867611 | Psoriasis and hypertension severity: results from a case-control study |
| Q37102789 | Psoriasis and metabolic disease: epidemiology and pathophysiology |
| Q35601338 | Psoriasis and metabolic syndrome |
| Q37095225 | Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study |
| Q35168945 | Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature |
| Q37540440 | Psoriasis comorbidities: complications and benefits of immunobiological treatment |
| Q43693973 | Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study |
| Q26765175 | Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background |
| Q37224763 | Psoriasis--new insights into pathogenesis and treatment |
| Q28088340 | Psoriasis: classical and emerging comorbidities |
| Q48317245 | Psoriasis: guidance on assessment and referral. |
| Q58004010 | Quoi de neuf en dermatologie clinique ? |
| Q26767276 | Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? |
| Q37553636 | Relationship between psoriasis and non-alcoholic fatty liver disease |
| Q51310396 | Serum Preptin and Amylin Values in Psoriasis Vulgaris and Behçet's Patients. |
| Q50776527 | Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. |
| Q33840850 | Serum fatty acid profile in psoriasis and its comorbidity |
| Q51370354 | Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome. |
| Q33941977 | Skin integrity in critically ill obese patients |
| Q35089915 | Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome |
| Q36946016 | The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients |
| Q36408491 | The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years |
| Q35199755 | The association of psoriasis and elevated blood lipids in overweight and obese children. |
| Q51350319 | The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. |
| Q37212524 | The effect of weight loss in obese patients with chronic stable plaque-type psoriasis |
| Q90576423 | The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: A randomized, open-labeled, active-controlled clinical trial |
| Q58727105 | The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis |
| Q34449302 | Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. |
| Q47126973 | Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry |
| Q37306962 | Upregulation of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis |
| Q45761302 | Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. |
| Q37523846 | Ustekinumab: a new option in psoriasis therapy |
| Q34041797 | Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis |
| Q83200986 | [Co-morbidities in psoriasis vulgaris] |
| Q84279858 | [Comorbidities in psoriasis] |
| Q87233775 | [Comorbidities in psoriatic arthritis] |
| Q84324604 | [How should one advance the current therapeutic strategies and objectives?] |
| Q81241819 | [Pathogenesis of the metabolic syndrome] |
| Q81241816 | [Psoriasis, metabolic syndrome and its components] |
| Q81817286 | [Severe psoriasis: beyond the skin, what are the risks of not treating the disease?] |
| Q83274168 | [Therapeutic strategies for psoriasis and psoriatic arthritis] |
Search more.